Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01544998 · ClinicalTrials.gov registry record · Phase 1
Tadalafil and Nesiritide as Therapy in Pre-clinical Heart Failure
A Phase 1 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 1
- Development phase
- 43
- Enrollment target
NCT01544998: Completed Phase 1 study, sponsored by Mayo Clinic.
NCT01544998 is a Phase 1 study that has completed, run by Mayo Clinic. The registered enrollment target is 43 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01544998, a Phase 1 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 43 participants
- Enrollment target
Study Summary
This study is being done to determine the effects of subcutaneous (under the skin) injection of human B-type natriuretic factor (BNP), Natrecor (nesiritide), a hormone produced by the heart, in combination with Tadalafil on: * The pumping function of the heart * Kidney function * Hormonal function (levels of different hormones in your blood) in persons with lower pumping function of their heart.
Interventions
- DRUG Placebo
- DRUG Tadalafil
- DRUG Nesiritide
- DRUG Saline load
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2012-02 |
| Est. Completion | 2014-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01544998
The ClinicalTrials.gov registry entry for NCT01544998 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT01544998 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01544998 about?
NCT01544998 is a clinical study titled "Tadalafil and Nesiritide as Therapy in Pre-clinical Heart Failure". This study is being done to determine the effects of subcutaneous (under the skin) injection of human B-type natriuretic factor (BNP), Natrecor (nesiritide), a hormone produced by the heart, in combination with Tadalafil on: * The pumping function of the heart * Kidney function * Hormonal function ...
What is the current status of trial NCT01544998?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 43 participants. The study started on 2012-02. Estimated completion is 2014-08.
What interventions are being tested in trial NCT01544998?
The interventions under investigation include: Placebo (DRUG), Tadalafil (DRUG), Nesiritide (DRUG), Saline load (DRUG).
Who is sponsoring clinical trial NCT01544998?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.